Quantcast
Last updated on April 19, 2014 at 7:29 EDT

Latest Panitumumab Stories

2013-09-16 08:28:57

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, September 16, 2013 /PRNewswire/ -- Today, Investors' Reports announced new research reports highlighting Amgen, Inc. (NASDAQ: AMGN), Gilead Sciences, Inc. (NASDAQ: GILD), Abbott Laboratories (NYSE: ABT), Biogen Idec Inc. (NASDAQ: BIIB), and UnitedHealth Group Inc. (NYSE: UNH). Today's readers may access these reports free of charge - including full price targets, industry analysis and...

2013-09-12 08:31:06

THOUSAND OAKS, Calif., Sept. 12, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will present new data from studies of marketed and pipeline products at the 17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress happening Sept. 27 to Oct. 1 in Amsterdam. "Amgen's continued focus on growth through innovation is highlighted by the data that we are presenting at the European Cancer Congress this year," said Sean E. Harper, M.D., executive vice president of Research and...

2013-09-11 16:24:27

Study Links RAS Mutations to Vectibix Clinical Response in Patients With Metastatic Colorectal Cancer THOUSAND OAKS, Calif., Sept. 11, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the publication of a biomarker analysis of Vectibix(®) (panitumumab) in combination with FOLFOX, a type of oxaliplatin-based chemotherapy, for the first-line treatment of patients with metastatic colorectal cancer (mCRC). Published in the New England Journal of Medicine, the analysis found that...

2013-06-03 10:54:17

A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression of a gene called MET, according to a study published in the June issue of Cancer Discovery, a journal of the American Association for Cancer Research. Preliminary data published in this study showed human tumors with MET amplification, grown in mice, responded to MET...

2013-05-15 20:23:18

Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix(®) (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new...

2013-05-15 20:22:49

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from several studies of both pipeline and marketed products at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago. "The data that we are presenting at ASCO demonstrate great progress with our effort to develop treatments that will help patients with advanced cancers," said Sean E. Harper, M.D., executive vice president of...

2013-05-07 16:28:43

Study Meets Primary Endpoint of Non-Inferiority in Monotherapy Setting THOUSAND OAKS, Calif., May 7, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 head-to-head ASPECCT ('763) trial evaluating Vectibix(®) (panitumumab) versus Erbitux(®) (cetuximab) as a single agent for the treatment of chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type KRAS tumors (n=1,010) met its primary endpoint of non-inferiority for overall survival. The...

2013-02-01 08:25:50

DALLAS, Feb. 1, 2013 /PRNewswire-iReach/ -- It is predicted that the global monoclonal antibody market scale will reach USD78 billion in 2012. Meanwhile, monoclonal antibody is also a key major source of blockbuster drugs. In 2011, the sales of six monoclonal antibody agents as Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab (Abbvie) and Trastuzumab (Roche) reached above USD5 billion around the globe, approximating 60% of global...

A Traffic Cop For Stopping Cancer Cells?
2013-01-15 05:53:23

Connie K. Ho for redOrbit.com — Your Universe Online Researchers from the Fox Chase Cancer Center recently discovered a novel method of improving cancer drugs, where they could block a specific pathway in the cell and provide an easier way for drugs to eliminate tumors. According to the American Cancer Society, cancer occurs when there is uncontrolled growth and expansion of abnormal cells. It is caused by external factors (such as chemicals, infectious organisms, radiation, and...

2012-06-18 06:29:14

BALTIMORE, Maryland and HAMBURG, Germany, June 18, 2012 /PRNewswire/ -- Two studies published back-to-back in last week's Nature applied DNA blood testing using the BEAMing technology to detect drug resistance mediated by KRAS mutations in colorectal cancer patients months before treatment failure was observed. The group led by Alberto Bardelli, PhD of the University of Torino, Italy describes the development of secondary resistance mutations to the anti-EGFR monoclonal...